Drug Profile
Olezarsen - Ionis Pharmaceuticals
Alternative Names: AKCEA-APOCIII-LRx; GalNAc3 conjugated antisense oligonucleotide - Ionis Pharmaceuticals; IONIS-APOCIII-LRx; IONISAPOCIII-LRx, sodium salt; ISIS 678354; ISIS-APOCIII-LRx; Olezarsen sodiumLatest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Developer Akcea Therapeutics; Ionis Pharmaceuticals
- Class Amides; Amino acids; Antihyperlipidaemics; Antisense oligonucleotides; Cardiovascular therapies; Drug conjugates
- Mechanism of Action Apolipoprotein C III expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Hyperlipoproteinaemia type I; Hypertriglyceridaemia
Most Recent Events
- 11 Apr 2024 Ionis Pharmaceuticals initiates an expanded-access programme for Hyperlipoproteinaemia type I (NCT06360237)
- 07 Apr 2024 Efficacy and safety data from the phase III BALANCE trial in Hyperlipoproteinaemia type I released by Ionis Pharmaceuticals
- 21 Feb 2024 Olezarsen - Ionis Pharmaceuticals receives Breakthrough Therapy status for Hyperlipoproteinaemia type I in USA